Literature DB >> 11993690

The neuroendocrine system and its tumors: an overview.

R A DeLellis1.   

Abstract

Neuroendocrine tumors comprise a family of neoplasms with a wide range of morphologic, functional, and behavioral characteristics. Their diagnosis depends on the recognition of characteristic morphologic features and on the presence of markers indicative of neuroendocrine differentiation. Neuroendocrine tumors can be grouped into epithelial and neural subtypes on the basis of the presence of cytokeratins or neurofilaments, respectively. The nomenclature of these tumors, particularly those of the epithelial type, remains controversial. For some tumor types, such as those of the anterior pituitary, thyroid, and parathyroid glands, the standard terminology is preferable to the terms neuroendocrine tumor or neuroendocrine carcinoma. The use of the term carcinoid, however, has become increasingly more inappropriate to describe the full range of neuroendocrine neoplasms of low to intermediate malignant potential. It is critical to convey in diagnostic teminology both the tumor type and its malignant potential. Diagnostic terms using neuroendocrine or endocrine together with information on grading and hormonal activity provide an optimal approach for the classification of these tumors. Additional studies, including gene expression profiling, will be critical for further advancing our understanding of the pathobiology and interrelationships of these neoplasms.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11993690     DOI: 10.1309/7GR5-L7YW-3G78-LDJ6

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  18 in total

1.  Perianal neuroendocrine tumor with suspected lymph node metastasis causing colonic compression and subsequent megacolon.

Authors:  Scott D Joudrey; Duane A Robinson; Robert Blair; Leslie D McLaughlin; Lorrie Gaschen
Journal:  Can Vet J       Date:  2015-03       Impact factor: 1.008

2.  Small-Cell Neuroendocrine Carcinoma of the Cervix Masquerading as a Cervical Fibroid: Report of a rare entity.

Authors:  Mukta Pujani; Kanika Singh; Varsha Chauhan; Raina Chawla; Rashmi Ahuja
Journal:  Sultan Qaboos Univ Med J       Date:  2018-04-04

3.  Primary large-cell neuroendocrine carcinoma of the scrotum.

Authors:  Anton Maricić; Miljenko Katunarić; Nikica Sutalo; Snjezana Tomic; Davor Jurisic; Marija Petkovic; Gordana Zamolo
Journal:  Wien Klin Wochenschr       Date:  2010-06-23       Impact factor: 1.704

Review 4.  Genes involved in neuroendocrine tumor biology.

Authors:  Eva Hofsli
Journal:  Pituitary       Date:  2006       Impact factor: 4.107

Review 5.  Neuroendocrine differentiation of prostate cancer: a review.

Authors:  Vamsi Parimi; Rajen Goyal; Kate Poropatich; Ximing J Yang
Journal:  Am J Clin Exp Urol       Date:  2014-12-09

Review 6.  Moderately differentiated neuroendocrine carcinoma (atypical carcinoid) of the parotid gland: report of three cases with contemporary review of salivary neuroendocrine carcinomas.

Authors:  Nasser Said-Al-Naief; Katherine Sciandra; Douglas R Gnepp
Journal:  Head Neck Pathol       Date:  2013-03-02

7.  A transgenic mouse model of metastatic carcinoma involving transdifferentiation of a gastric epithelial lineage progenitor to a neuroendocrine phenotype.

Authors:  Andrew J Syder; Sherif M Karam; Jason C Mills; Joseph E Ippolito; Habib R Ansari; Vidya Farook; Jeffrey I Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-30       Impact factor: 11.205

Review 8.  Neuroendocrine Neoplasms of the Sinonasal Tract: Neuroendocrine Carcinomas and Olfactory Neuroblastoma.

Authors:  Ketan Shah; Bayardo Perez-Ordóñez
Journal:  Head Neck Pathol       Date:  2016-02-01

9.  Safety and efficacy of everolimus in adult patients with neuroendocrine tumors.

Authors:  Paul E Oberstein; M Wasif Saif
Journal:  Clin Med Insights Oncol       Date:  2012-01-04

10.  Chemo-hormone therapy of non-well-differentiated endocrine tumours from different anatomic sites with cisplatinum, etoposide and slow release lanreotide formulation.

Authors:  P Correale; A Sciandivasci; C Intrivici; A Pascucci; M T Del Vecchio; S Marsili; V Savelli; L Voltolini; M Di Bisceglie; A Guarnieri; G Gotti; G Francini
Journal:  Br J Cancer       Date:  2007-04-17       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.